Introduction
============

In contrast to acute lymphoblastic leukemia, acute myeloid leukemia (AML) rarely involves the central nervous system (CNS) in adult patients while it is more common in pediatric AML patients.[@b1-cmar-9-097],[@b2-cmar-9-097] Therefore, routine diagnostic evaluation or prophylactic CNS therapy in adult AML is not performed, although some authors recommend a routine evaluation when hyperleukocytosis is present at diagnosis.[@b3-cmar-9-097],[@b4-cmar-9-097] Bojsen-Moller and Nielsen performed an autopsy study and found leukemic CNS infiltrates in 46% of all AML patients, which could point to higher rates of asymptomatic CNS involvement, but might be biased since the remission status of the studied patients was not approximated, and an autopsy study usually includes more patients with unfavorable and relapsed disease.[@b5-cmar-9-097] However, symptoms of CNS involvement may develop later during disease progression or at relapse, which might influence the outcome. Furthermore, CNS involvement might be diagnosed through the appearance of either leukemic blasts in the cerebrospinal fluid (CSF) and/or with intracerebral myeloid sarcoma or meningeal AML. Risk factors identified so far include high initial white blood cell (WBC) count in the peripheral blood and AML M5 French--American--British (FAB) morphology.[@b6-cmar-9-097] Several treatment options such as cranial and/or neuro-axis irradiation and intrathecal therapy (ITC) with methotrexate (MTX) and/or cytosine arabinoside (Ara-C) and glucocorticoids along with systemic chemotherapy are widely accepted.[@b7-cmar-9-097]--[@b10-cmar-9-097] Little is known regarding CNS involvement in adult AML and its impact on survival since most studies examined pediatric patients or only a limited number of patients.[@b8-cmar-9-097],[@b11-cmar-9-097]--[@b15-cmar-9-097] Therefore, the present study analyzed CNS involvement in patients with AML treated in the prospective AML96, AML2003, and AML60+ trials of the "Study Alliance Leukemia" (SAL) study group for a better understanding of this rare AML entity and to identify patient populations that are at increased risk for CNS disease. This report represents the largest cohort of AML patients analyzed with respect to CNS involvement to date.

Patients and methods
====================

Between February 1996 and November 2009, 3,526 adult patients with non-acute promyelocytic leukemia AML were included in the prospective AML96, AML2003, and AML60+ trials of the SAL. The studies were approved by the ethics committees of the University of Dresden and all other participating centers. A list of participating centers and ethics committees can be found in the [Supplementary material](https://www.dovepress.com/get_supplementary_file.php?f=125259.pdf). The protocols were in agreement with the Helsinki declaration and registered with NCT numbers 00180115 (AML96), 00180102 (AML2003), and 00180167 (AML60+). Written informed consent was obtained from all patients. Data were collected and certified by the SAL Data Center.

In the AML96 protocol, patients \<60 years of age were treated with double induction chemotherapy including standard- and intermediate-dose mitoxantrone, Ara-C, etoposide, and amsacrine and stratified post-remission therapy in different cytogenetic risk groups. Intermediate risk patients with a human leukocyte antigen (HLA)-identical sibling donor were referred to allogeneic hematopoietic stem cell transplant (HSCT). High risk patients were referred to related or unrelated HLA-compatible allogeneic HSCT.[@b16-cmar-9-097] Patients without donors were randomized to intermediate-dose or high-dose Ara-C and mitoxantrone and subsequent autologous HSCT. Patients \>60 years of age received double induction chemotherapy with daunorubicin and standard-dose Ara-C followed by consolidation therapy consisting of intermediate-dose Ara-C and amsacrine.[@b17-cmar-9-097]

In the AML60+ trial, patients \>60 years of age were included and randomized between the treatment arm of the AML96 study for elderly patients and induction with intermediate-dose Ara-C and mitoxantrone. Allogeneic HSCT was optional for fit patients.[@b18-cmar-9-097]

The AML2003 trial included patients below the age of 61 years. Patients were randomized up-front in a two-by-two factorial design with the two factors high-dose Ara-C alone versus high-dose Ara-C plus mitoxantrone and amsacrine for consolidation and standard versus risk adapted intensified consolidation including early allogeneic HSCT during induction therapy and autologous HSCT. All patients received a 3+7 regimen with daunorubicin and Ara-C as induction chemotherapy.

In the presence of neurologic or psychiatric abnormalities, lumbar puncture was performed to confirm or exclude CNS involvement through microscopy and/or flow cytometry of the CSF in all three prospective trials. CNS disease was treated with ITC with MTX, Ara-C, and glucocorticoids. Treatment response and treatment outcome were defined according to the recommended consensus criteria.[@b19-cmar-9-097] Data of proven extramedullary manifestations were available in 3,261 patients, which were included in this study. The patient characteristics are summarized in [Table 1](#t1-cmar-9-097){ref-type="table"}. The distributions of cytogenetic, molecular, clinical, and laboratory parameters were compared in order to identify risk factors for CNS involvement. The chi-square test was used for significance testing of comparisons in categorical variables and the Mann--Whitney *U* test for continuous variables. Kaplan--Meier method was used to estimate the overall survival (OS). Survival distributions were compared using the log-rank test.

Results
=======

For this study, all 3,261 patients were analyzed with a median follow-up of 5.1 years. A total of 21 patients had CNS involvement at the time of initial presentation resulting in a prevalence of 0.6%. CNS involvement at AML relapse had a statistically higher incidence of 2.9% with 34 affected patients among 1,154 patients at relapse versus 21 of 3,261 patients at initial diagnosis (*p*\<0.010).

Characteristics and outcome of CNS disease at initial diagnosis were further analyzed ([Table 1](#t1-cmar-9-097){ref-type="table"}). The majority of patients (n=18, 86%) had de novo AML. The median age of these patients was 54 years (range 22--77 years). Gender and age were equally distributed between patients with CNS involvement and patients without CNS involvement. Extramedullary AML other than CNS was present more frequently in patients with CNS involvement as compared to patients without CNS involvement (n=13, 62% vs n=344, 11%, *p*\<0.001).

Significantly more patients with CNS involvement had *FLT3*--internal tandem duplication (ITD) mutations (n=8, 44% vs n=611, 21%, *p*=0.017) and when grouping *FLT3*--ITD and *NPM1* mutations, there was a statistically significant higher occurrence of combined *FLT3*--ITD and *NPM1* mutations in patients with CNS involvement as compared to those without CNS involvement (n=7, 44% vs n=335, 12%, *p*=0.002). Furthermore, patients with CNS involvement exhibited significantly higher levels of lactate dehydrogenase activity (LDH) (log U/l 2.81 vs 2.59, *p*=0.023) (base 10 logarithm), higher frequencies of FAB M5 morphology (n=8, 38% vs n=417, 13%, *p*=0.001) compared with patients without CNS involvement. When analyzing patients at initial diagnosis, complex aberrant karyotypes were significantly more frequent in patients with CNS involvement compared with those without CNS involvement (n=6, 29% vs n=398, 12%, *p*=0.025).

Fourteen of 21 patients with CNS involvement at initial diagnosis were treated with ITC. Survival and complete remission rates for these patients were analyzed. Patients with CNS involvement reached complete remission less frequently than patients without CNS involvement (n=10, 48% vs n=2,317, 72%, *p*=0.016), and had a significantly inferior outcome even if treated with ITC with an OS of 11% (95% confidence interval \[CI\], 0%--25%) versus 30% (95% CI, 28%--32%) at 5 years, *p*=0.004 ([Figure 1](#f1-cmar-9-097){ref-type="fig"}).

Discussion
==========

AML rarely involves the CNS in adults and there are only a few published studies with controversial results.[@b9-cmar-9-097],[@b20-cmar-9-097],[@b21-cmar-9-097] CNS involvement may remain asymptomatic. Diagnostic lumbar puncture or prophylactic ITC is not routinely recommended without CNS symptoms. Systemic therapy for isolated CNS involvement in parallel to cranial irradiation and/or ITC seems to be necessary in order to avoid marrow relapse.[@b22-cmar-9-097],[@b23-cmar-9-097]

This study analyzes the largest data set of adult AML patients with proven CNS involvement reported so far. An overall prevalence of 0.6% was found at initial diagnosis which is lower than previously reported prevalence ranging between 2% and 8%.[@b1-cmar-9-097],[@b24-cmar-9-097],[@b25-cmar-9-097] One possible reason of higher rates in the earlier reports could be the fact that some of these studies were done in pediatric patients while others included promyelocytic leukemia, used imaging studies with magnetic resonance imaging instead of lumbar puncture, or included patients at relapse as well.[@b24-cmar-9-097]--[@b28-cmar-9-097] However, some of these imaging data might be conflicting since they possibly rather represent intracerebral myeloid sarcoma, meningeal AML, or simply inflammatory enhancement. Furthermore, the data from the present analysis reflect only the patients in whom manifestation of CNS involvement was clinically apparent due to neurological and/or psychiatric symptoms. Thus, this could implicate that the real prevalence including asymptomatic CNS involvement is higher, although another study suggested that this might not be the case.[@b29-cmar-9-097]

In this analysis, symptomatic CNS involvement was frequently accompanied by other extramedullary AML manifestations and higher prevalence of *FLT3*--ITD mutations, whereas *NPM1* mutations alone had no significant higher incidence in these patients. As previously shown, FAB M5 morphology, complex aberrant karyotype, higher LDH levels, and higher WBC count at diagnosis represent risk factors for CNS involvement.[@b3-cmar-9-097],[@b8-cmar-9-097],[@b13-cmar-9-097],[@b25-cmar-9-097] Interestingly, other studies showed an association of CNS involvement in AML with certain cytogenetic abnormalities such as inv(16), del(5q), del(7q), trisomy of chromosome 8, t(8;21), and abnormalities of chromosome 11q23, which could not be confirmed for patients with CNS involvement at the initial diagnosis of AML.[@b25-cmar-9-097],[@b30-cmar-9-097],[@b31-cmar-9-097]

However, upon extending the data analysis by including also CNS involvement of AML at relapse, statistically significant higher incidence of CNS involvement was confirmed for patients with trisomy of chromosome 8, trisomy of chromosome 22, t(9;11), t(6;11), and complex karyotype. The study could not confirm a higher prevalence for patients with t(8;21), inv(16), monosomy of chromosome 5, or monosomy of chromosome 7 ([Table 2](#t2-cmar-9-097){ref-type="table"}). In total, abnormalities of chromosome 11q23 were evident in 20% of all AML patients with CNS involvement either at initial diagnosis or at relapse of CNS involvement (n=11/55). In 7 patients 11q23 abnormalities were only detected using FISH analysis (Fluorescence in situ hybridization). In these cases the 11q23 translocation was cryptic by karyotyping. This reflects a higher prevalence of 11q23 abnormalities than the estimated 6% in AML with a higher occurrence in myelomonocytic AML.[@b32-cmar-9-097],[@b33-cmar-9-097] Hence, data from the present analysis confirm the previously reported higher occurrence of 11q23 abnormalities of patients with CNS disease as reported by others recently.[@b13-cmar-9-097],[@b25-cmar-9-097],[@b34-cmar-9-097]

The impact of CNS involvement on long-term treatment outcome has been discussed controversially.[@b4-cmar-9-097],[@b8-cmar-9-097],[@b10-cmar-9-097],[@b21-cmar-9-097] Recently, Shihadeh et al suggested that adult AML patients with CNS involvement have poor OS.[@b25-cmar-9-097] The present study could confirm this finding based on the largest number of patients with CNS involvement and define further risk factors (*FLT3*--ITD mutations, complex aberrant karyotypes) that might help to identify AML patients at risk for CNS involvement ([Figure 2](#f2-cmar-9-097){ref-type="fig"}). However, due to the low frequency and low ITC chemotherapy-initiation at diagnosis in the three reported AML trials, differently sized patient cohorts have been compared and the statistical impact must be interpreted carefully. In summary, this analysis suggests a very low frequency of symptomatic CNS AML involvement in adults. Because of the obviously poor prognosis of CNS involvement, screening for risk factors of CNS involvement at diagnosis in symptomatic AML patients with suspicion for CNS involvement may be useful to identify a patient population benefiting from intensified treatment strategies in the future.

The contribution of all patients and physicians in the various trials of the German SAL is highly appreciated. This study was presented in part at the 17th Annual Congress of the European Hematology Association, June 14--17, 2012, Amsterdam, the Netherlands.

**Disclosure**

The authors report no conflicts of interests in this work.
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![Risk factors for symptomatic AML patients with potential CNS involvement at initial diagnosis of AML.\
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###### 

Comparison of patients' characteristics between AML patients with and without CNS involvement at diagnosis

                                                                                          AML patients at diagnosis n=3,261   *p*-Value           
  --------------------------------------------------------------------------------------- ----------------------------------- ------------------- -------
  Trials                                                                                                                                          
   AML96, n                                                                               16                                  1,632               
   AML2003, n                                                                             3                                   1,156               
   AML60+, n                                                                              2                                   452                 NA
  Gender, n (%)                                                                                                                                   
   Female                                                                                 12 (57)                             1,630 (50)          0.496
   Male                                                                                   9 (43)                              1,610 (50)          
  Median age at diagnosis, years (range)                                                  54 (22--77)                         57 (15--87)         0.904
  Median WBC log mean ×10^9^/L (range)[\*](#tfn1-cmar-9-097){ref-type="table-fn"}         1.13 (0.14--2.41)                   1.06 (0--2.67)      0.054
  Median platelets log mean ×10^9^/L (range)[\*](#tfn1-cmar-9-097){ref-type="table-fn"}   1.9 (1.04--2.37)                    1.72 (0--3.12)      0.334
  FAB classification at diagnosis, n (%)                                                                                                          
   M0                                                                                     1 (5)                               160 (5)             0.962
   M1                                                                                     4 (19)                              702 (22)            0.754
   M2                                                                                     5 (24)                              963 (30)            0.536
   M4                                                                                     3 (14)                              509 (16)            0.843
   M5                                                                                     8 (38)                              438 (14)            0.001
   M6                                                                                     0 (0)                               103 (3)             0.404
   M7                                                                                     0 (0)                               22 (1)              0.703
  Complex aberrant cytogenetic karyotype, n (%)                                           6 (29)                              398 (12)            0.025
  Cytogenetic risk, n (%)                                                                                                                         
   Adverse                                                                                7 (33)                              695 (22)            0.239
   Intermediate                                                                           14 (67)                             2,331 (72)          
   Favorable                                                                              0 (0)                               214 (7)             
  LDH log U/L (range)[\*](#tfn1-cmar-9-097){ref-type="table-fn"}                          2.81 (2.16--3.86)                   2.56 (0.38--4.22)   0.008
  Extramedullary AML other than CNS, n (%)                                                13 (62)                             344 (11)            0.001
  *FLT3*--ITD positive, n (%)                                                             8 (44)                              611 (21)            0.017
  *NPM1* mut, n (%)                                                                       8 (50)                              834 (30)            0.078
  *FLT3*--ITD/*NPM1*, n (%)                                                                                                                       
   *FLT3*--ITD neg/*NPM1* neg                                                             7 (44)                              1,668 (60)          
   *FLT3*--ITD neg/*NPM1* pos                                                             1 (6)                               265 (10)            0.002
   *FLT3*--ITD pos/*NPM1* neg                                                             1 (6)                               494 (18)            
   *FLT3*--ITD pos/*NPM1* pos                                                             7 (44)                              335 (12)            
  Complete remission (including CRi), n (%)                                               10 (48)                             2,317 (72)          0.016
  Allogeneic stem cell transplantation, n (%)                                             6 (29)                              556 (17)            0.045

**Note:**

Calculated as base 10 logarithms.

**Abbreviations:** AML, acute myeloid leukemia; CNS, central nervous system; LDH, lactate dehydrogenase activity; ITD, internal tandem duplication; FAB, French--American--British; NA, not applicable; pos, positive; neg, negative; mut, mutation; WBC, white blood cell.

###### 

Comparison of cytogenetic profile between AML patients with and without CNS involvement at diagnosis or relapse

  Cytogenetic profile       AML patients at diagnosis n=3,261   *p*-Value    
  ------------------------- ----------------------------------- ------------ -------
  Normal karyotype, n (%)   16 (31)                             1,472 (50)   0.158
  Trisomy 8, n (%)          10 (21)                             254 (8)      0.001
  Trisomy 22, n (%)         3 (6)                               62 (2)       0.034
  Trisomy 11, n (%)         1 (2)                               35 (1)       0.514
  Trisomy 13, n (%)         1 (2)                               42 (1)       0.641
  Trisomy 21, n (%)         2 (4)                               69 (2)       0.343
  Monosomy 5, n (%)         0 (0)                               26 (1)       0.531
  Monosomy 7, n (%)         0 (0)                               144 (4)      0.133
  t(3;3), n (%)             0 (0)                               8 (1)        0.729
  t(1;7), n (%)             0 (0)                               1 (0)        0.903
  t(6;11), n (%)            1 (2)                               6 (0)        0.005
  t(8;21), n (%)            2 (4)                               128 (4)      0.951
  t(9;11), n (%)            3 (6)                               41 (1)       0.003
  t(6;9), n (%)             0 (0)                               22 (1)       0.565
  t(9;22), n (%)            0 (0)                               7 (1)        0.746
  t(11;19), n (%)           0 (0)                               16 (1)       0.624
  inv(16), n (%)            3 (6)                               150 (5)      0.610
  Inv(3) (q21q26)           0 (0)                               20 (1)       0.583

**Abbreviations:** AML, acute myeloid leukemia; CNS, central nervous system.
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